Thermo Fisher Scientific Launches CE-IVD (IVDD) Next-Generation Sequencing Test and Analysis Software to Expand Access to Precision Oncology Biomarker Testing

Next-generation sequencing (NGS) is quickly becoming the platform of choice for tumor molecular profiling due to its ability to simultaneously report on multiple biomarkers. However, lengthy turnaround times can limit the clinical utility of these results. To meet the need for rapid genomic insights, Thermo Fisher Scientific today launched the CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx for use in clinical labs.

Industry-leading Risk-Based Quality Management event focuses on the maturity of RBQM, its increasing value, and the vision for the future

Industry-leading Risk-Based Quality Management event focuses on the maturity of RBQM, its increasing value, and the vision for the future CluePoints Hosts RBQM Live 2022 as the Premier Event Sponsor

ZeOmega Recognized in KLAS Research CMS Payer Interoperability 2022 Vendor Guide

ZeOmega®, the leading population health management organization, today announced that it is featured in the KLAS Research CMS Payer Interoperability 2022 Vendor Guide. The report lists ZeOmega as one of the top performing companies whose solutions help payers comply with regulations for secure data exchange.

Rho Announces Findings from Study it Coordinated to Explore Therapy for Reducing Asthma Attacks Among Disadvantaged Urban Youth

Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced findings from a clinical trial it supported as the Statistical and Clinical Coordinating Center for the Inner-City Asthma Consortium (ICAC) to assess the efficacy of a monoclonal antibody for reducing asthma attacks in disadvantaged urban youth.

MMS Announces Key Executive Appointment to Support Company's Next Stage of Growth

MMS Holdings, a data-focused contract research organization, announced the appointment of Kelly J. Hill to Chief Strategy Officer. This announcement comes as the company is accelerating in growth after its partnership with a private equity firm.

Lifeasible Helps Resolve Insect and Mollusc Genome Detection Issues

Matexcel Enlarged Its Raw Materials Offerings for Bone Implants

Creative BioMart Updated Its Protein Engineering Rational Design Services

Profacgen Announces New Fermentation Process Development Solutions

Biopharma PEG Provides PEG Derivatives Used As PROTAC Linker

Huateng Pharma Supplies SGLT-2 inhibitors Against Type 2 Diabetes

ChargePoint Technology Acquires PuroVaso

SHORTLIST ANNOUNCED FOR INAUGURAL SUSTAINABLE MEDICINES PACKAGING AWARDS

MicrobioSeq Boosts Microbial Community Research with Long-Read Metagenomic Sequencing

CD Genomics RNA-Solutions Platform Announces the Launch of Nanopore Direct RNA Sequencing

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III Study in Patients with Atrial Fibrillation

A leader in continuous remote patient monitoring and data analytics, physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases. Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, recommended physIQ’s innovative monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation (AF) – one of the most common heart arrhythmias that affects one in four adults over the age of 40.1

Thermo Fisher Scientific Expands Viral Vector Manufacturing Capabilities

Lonza Strengthens Micronization Portfolio with the Introduction of X-Ray Powder Diffraction Capability in Monteggio (CH)

Athenex Partners with Leading Contract Manufacturer GenScript ProBio in the Development of Advanced Cell and Gene Therapies

GenScript ProBio announced that it has expanded its partnership with Athenex which is a leading biopharmaceutical business that is committed to the development, discovery and commercialization of innovative therapies to treat cancer and related disorders as well as the creation of cutting-edge treatments for gene and cell therapy with the benefit of a preferred collaboration.

Cellefill™, a new integrated solution to fast-track cell, gene and biological therapies